Please assess the completion status of the following clinical trial:

Trial Title: An Innovative Treatment for Fistula-in-ano in Crohn Disease : Local Micro Reinjection of Autologous Fat and SVF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Disease of Crohn diagnosed for at least 6 months according to the recognized clinical, endoscopic and histological criteria~* Presence of fistulas died anal complex estimated by clinical examination and MRI. A fistula died anal complex is, by definition, a fistula which answers at least one of the following criteria during its evolution: (1) high, trans-sphincter, extra-sphincter or above sphincter Inter-sphincter. (2) Presence of = 2 external openings. (3) Purulent Collections associated~* Active or slightly active Crohn luminal, defined by a CDAI (Crohn's Disease Activity Index) = 220~Exclusion Criteria:~- Disease of Crohn activates mainly luminal with a CDAI = 220 requiring an immediate treatment~* Patients having never received specific treatments of the anal died disease of Crohn with fistula, including by antibiotics~* Presence of an abscess or collections of more than 2 cms unless this problem is solved during the period of preparation~* Rectal and/or anal Stenosis and/or active proctitis, if it means a limitation of the surgical procedure~* Patient having undergone an operation of the fistula other than the drainage~* Patients under corticoids or by having receiving in the previous four weeks~* Active Malignant Tumors or history of Malignant tumors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Crohn's disease treated by SVF (Type: EXPERIMENTAL): Patients with Crohn's disease and fistula-in-ano refractory to conventional medical and surgical treatment, treated by Stromal Vascular Fraction ( SVF) reinjection

Based on this trial design, predict the completion outcome and termination type (if applicable).